Apyx Medical (APYX) Competitors $2.06 +0.03 (+1.48%) Closing price 04:00 PM EasternExtended Trading$2.00 -0.06 (-3.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APYX vs. NPCE, DRTS, TCMD, SKIN, CATX, SMTI, NNOX, BWAY, OM, and STIMShould you be buying Apyx Medical stock or one of its competitors? The main competitors of Apyx Medical include NeuroPace (NPCE), Alpha Tau Medical (DRTS), Tactile Systems Technology (TCMD), Beauty Health (SKIN), Perspective Therapeutics (CATX), Sanara MedTech (SMTI), Nano-X Imaging (NNOX), Brainsway (BWAY), Outset Medical (OM), and Neuronetics (STIM). These companies are all part of the "medical equipment" industry. Apyx Medical vs. Its Competitors NeuroPace Alpha Tau Medical Tactile Systems Technology Beauty Health Perspective Therapeutics Sanara MedTech Nano-X Imaging Brainsway Outset Medical Neuronetics Apyx Medical (NASDAQ:APYX) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Which has more risk & volatility, APYX or NPCE? Apyx Medical has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Does the media favor APYX or NPCE? In the previous week, NeuroPace had 25 more articles in the media than Apyx Medical. MarketBeat recorded 26 mentions for NeuroPace and 1 mentions for Apyx Medical. NeuroPace's average media sentiment score of 0.70 beat Apyx Medical's score of 0.00 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apyx Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroPace 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, APYX or NPCE? Apyx Medical has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApyx Medical$48.10M1.62-$23.46M-$0.45-4.58NeuroPace$79.91M3.57-$27.14M-$0.84-10.26 Is APYX or NPCE more profitable? NeuroPace has a net margin of -29.29% compared to Apyx Medical's net margin of -37.11%. Apyx Medical's return on equity of -158.22% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets Apyx Medical-37.11% -158.22% -28.30% NeuroPace -29.29%-168.61%-25.48% Do analysts recommend APYX or NPCE? NeuroPace has a consensus target price of $16.60, indicating a potential upside of 92.58%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts plainly believe NeuroPace is more favorable than Apyx Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apyx Medical 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.67NeuroPace 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals and insiders believe in APYX or NPCE? 55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 15.2% of Apyx Medical shares are owned by company insiders. Comparatively, 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryNeuroPace beats Apyx Medical on 12 of the 17 factors compared between the two stocks. Get Apyx Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for APYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APYX vs. The Competition Export to ExcelMetricApyx MedicalMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.91M$10.65B$5.73B$9.56BDividend YieldN/A1.89%4.53%4.08%P/E Ratio-4.5820.5430.4625.16Price / Sales1.6230.41392.5787.62Price / CashN/A24.4637.0358.50Price / Book10.303.388.956.21Net Income-$23.46M$211.77M$3.26B$265.38M7 Day Performance-2.83%0.86%1.06%-1.13%1 Month Performance-8.04%9.93%4.31%-0.71%1 Year Performance67.48%-10.79%28.39%18.86% Apyx Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APYXApyx Medical1.2749 of 5 stars$2.06+1.5%N/A+58.6%$77.91M$48.10M-4.58270NPCENeuroPace3.4543 of 5 stars$8.42-1.6%$16.60+97.1%+19.6%$283.18M$79.91M-10.02170Short Interest ↑Analyst RevisionDRTSAlpha Tau Medical2.5648 of 5 stars$3.26-0.6%$9.00+176.1%+40.4%$278.21MN/A-6.7980News CoverageTCMDTactile Systems Technology2.713 of 5 stars$12.58+1.4%$13.50+7.3%+0.6%$276.64M$298.85M20.291,037Positive NewsSKINBeauty Health1.7122 of 5 stars$2.19+0.5%$2.63+19.9%+44.2%$276.48M$334.30M-7.821,030CATXPerspective Therapeutics1.5657 of 5 stars$3.69+2.2%$12.56+240.3%-77.2%$268.09MN/A0.0070Trending NewsAnalyst RevisionSMTISanara MedTech2.2509 of 5 stars$31.58+6.4%$50.00+58.3%-4.7%$264.22M$86.67M-27.2260News CoverageAnalyst ForecastAnalyst RevisionNNOXNano-X Imaging2.3377 of 5 stars$4.26-3.6%$8.50+99.5%-45.3%$255.38M$11.28M-4.73190BWAYBrainsway3.294 of 5 stars$14.85+14.4%$18.00+21.2%+88.6%$245.33M$41.02M57.12120News CoverageShort Interest ↓Analyst RevisionHigh Trading VolumeOMOutset Medical1.5081 of 5 stars$13.67+2.9%$24.67+80.4%+50.7%$236.11M$113.69M-0.67520News CoverageAnalyst ForecastSTIMNeuronetics2.3631 of 5 stars$3.54+6.0%$7.00+97.7%+226.5%$234.08M$111.11M-3.13180Positive News Related Companies and Tools Related Companies NPCE Competitors DRTS Competitors TCMD Competitors SKIN Competitors CATX Competitors SMTI Competitors NNOX Competitors BWAY Competitors OM Competitors STIM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APYX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apyx Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Apyx Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access